Phase II study of DFP-14323 with low dose EGFR-TKI for EGFR mutation positive NSCLC.
Phase 2
- Conditions
- SCLC
- Registration Number
- JPRN-UMIN000033062
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 26
Inclusion Criteria
Not provided
Exclusion Criteria
Patients without 1) Contraindicated cases for Erlotinib or Afatinib or Osimertinib 2) Obvious infections 3) T790M, exon20 ins 4) Severe heart diseases 5) Severe complications 6) Brain metasitases 7) Severe digestive diseases 8) Severe thromboembolisms 9) Severe diarrhea 10) Severe psychosis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease Control Rate(DCR)
- Secondary Outcome Measures
Name Time Method Efficacy 1)Objective Response Rate 2)Nuetrophil/Lymphocyte Rate 3)Tumor Maker Safety Rate of AE and SE